普瑞眼科
(301239)
| 流通市值：60.54亿 | | | 总市值：63.77亿 |
| 流通股本：1.42亿 | | | 总股本：1.50亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 820,353,329.11 | 2,797,261,037.47 | 2,200,549,440.39 | 1,459,262,003.44 |
| 营业收入 | 820,353,329.11 | 2,797,261,037.47 | 2,200,549,440.39 | 1,459,262,003.44 |
| 二、营业总成本 | 726,043,058.39 | 2,746,109,913.2 | 2,105,665,391.88 | 1,389,064,906.77 |
| 营业成本 | 483,224,184.77 | 1,792,714,036.5 | 1,383,805,105.27 | 917,406,717.06 |
| 税金及附加 | 1,414,255.72 | 6,397,538.12 | 3,466,634.94 | 3,111,003.37 |
| 销售费用 | 137,927,875.45 | 518,364,310.43 | 405,712,336.68 | 258,212,409.03 |
| 管理费用 | 79,589,016.99 | 329,573,589.03 | 238,698,479.04 | 161,219,013.72 |
| 研发费用 | 2,442,210.9 | 10,816,545.79 | 8,086,821.35 | 5,343,459.43 |
| 财务费用 | 21,445,514.56 | 88,243,893.33 | 65,896,014.6 | 43,772,304.16 |
| 其中:利息费用 | 20,128,944.67 | 85,150,529.14 | 65,279,202.04 | 42,615,673 |
| 其中:利息收入 | 377,310.29 | 4,201,257.26 | 3,434,600.91 | 2,464,186.62 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -725,856.07 | 724,164.39 | 220,801.48 | -90,787.56 |
| 加:投资收益 | -316,782.29 | -10,892,876.65 | -2,523,117.09 | -811,598.95 |
| 资产处置收益 | -46,603.42 | 668.66 | 219,763.21 | 346,152.23 |
| 资产减值损失(新) | -628,020.14 | -11,357,225.83 | -1,117,190.62 | -902,137.44 |
| 信用减值损失(新) | -778,902.48 | -1,799,845.98 | -2,301,785.88 | -1,298,793 |
| 其他收益 | 2,433,056.8 | 3,248,373.86 | 1,669,610.08 | 790,199.77 |
| 四、营业利润 | 94,247,163.12 | 31,074,382.72 | 91,052,129.69 | 68,230,131.72 |
| 加:营业外收入 | 303,345.22 | 1,270,620.5 | 1,364,475.92 | 694,466.14 |
| 减:营业外支出 | 2,062,438.88 | 19,829,378.14 | 12,586,509.45 | 8,214,568.12 |
| 五、利润总额 | 92,488,069.46 | 12,515,625.08 | 79,830,096.16 | 60,710,029.74 |
| 减:所得税费用 | 19,490,579 | 66,234,455.94 | 58,241,549.1 | 42,897,414.39 |
| 六、净利润 | 72,997,490.46 | -53,718,830.86 | 21,588,547.06 | 17,812,615.35 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 72,997,490.46 | -53,718,830.86 | 21,588,547.06 | 17,812,615.35 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 70,645,328.36 | -60,922,620.1 | 16,349,147.04 | 14,667,471.77 |
| 少数股东损益 | 2,352,162.1 | 7,203,789.24 | 5,239,400.02 | 3,145,143.58 |
| 扣除非经常损益后的净利润 | 70,834,676.76 | -48,206,091.88 | 24,669,849.14 | 20,780,937.27 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.47 | -0.41 | 0.11 | 0.1 |
| (二)稀释每股收益 | 0.47 | -0.41 | 0.11 | 0.1 |
| 八、其他综合收益 | - | 29,078.28 | - | - |
| 归属于母公司股东的其他综合收益 | - | 29,078.28 | - | - |
| 九、综合收益总额 | 72,997,490.46 | -53,689,752.58 | 21,588,547.06 | 17,812,615.35 |
| 归属于母公司股东的综合收益总额 | 70,645,328.36 | -60,893,541.82 | 16,349,147.04 | 14,667,471.77 |
| 归属于少数股东的综合收益总额 | 2,352,162.1 | 7,203,789.24 | 5,239,400.02 | 3,145,143.58 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-28 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |